Pulsatile Secretion of Alpha-MSH and the Differential Effects of Dexamethasone and Haloperidol on the Secretion of Alpha-MSH and ACTH in Dogs
Overview
Authors
Affiliations
This study was performed to determine whether, in the dog, there is at any time pulsatile release of alpha-MSH and whether secretion of ACTH from the pars intermedia (PI) contributes to the circulating concentrations of ACTH. The 24-h secretory profiles of alpha-MSH, ACTH, and cortisol were determined in eight dogs. Plasma samples were obtained at 10-min intervals via an indwelling jugular catheter during two 12-h periods. Pulsatile secretion of alpha-MSH was found in all dogs, with wide variations in peak height. Plasma alpha-MSH levels were usually low (mean 15 pmol/l), but brief, distinct periods of increased plasma alpha-MSH concentrations as high as 489 pmol/l were found. Analysis of pulse frequency revealed a mean of 4.75 significant alpha-MSH peaks/24 h. The highest alpha-MSH peaks were associated with definite changes in the plasma concentrations of ACTH. In separate studies, the influence of dexamethasone on the 6-h secretory profiles and on the haloperidol-stimulated secretion of alpha-MSH, ACTH, and cortisol was investigated. In these two studies, plasma ACTH was measured by a highly sensitive immunoradiometric assay. Dexamethasone pretreatment significantly suppressed the plasma concentrations of ACTH, cortisol, and alpha-MSH to 10.3%, 3.9%, and 74.6% respectively. Dexamethasone pretreatment also significantly reduced the haloperidol-stimulated secretion of ACTH and cortisol, but had no influence on the haloperidol-stimulated secretion of alpha-MSH. After the administration of haloperidol to the dexamethasone-pretreated dogs, there were small increases in the plasma concentrations of ACTH and cortisol, the latter being significant. These data demonstrate that alpha-MSH is secreted spontaneously in a pulsatile manner in the dog and suggest that the canine PI contributes to circulating ACTH concentrations.
Pijnacker T, Knies M, Galac S, Sanders K, Mol J, Kooistra H Vet Q. 2018; 38(1):72-78.
PMID: 30362899 PMC: 6830985. DOI: 10.1080/01652176.2018.1521537.
Srithunyarat T, Hagman R, Hoglund O, Stridsberg M, Olsson U, Hanson J BMC Res Notes. 2017; 10(1):129.
PMID: 28327184 PMC: 5359833. DOI: 10.1186/s13104-017-2450-y.
Carbenoxolone Disodium Treatment for Canine Pituitary-Dependent Hyperadrenocorticism.
Teshima T, Matsumoto H, Okusa T, Uchiyama R, Koyama H PLoS One. 2016; 11(11):e0166267.
PMID: 27824928 PMC: 5100902. DOI: 10.1371/journal.pone.0166267.
Effects of Carbenoxolone on the Canine Pituitary-Adrenal Axis.
Teshima T, Matsumoto H, Okusa T, Nakamura Y, Koyama H PLoS One. 2015; 10(8):e0135516.
PMID: 26262685 PMC: 4532459. DOI: 10.1371/journal.pone.0135516.
Effects of a branched-chain amino acid-enriched diet on chronic hepatic encephalopathy in dogs.
Meyer H, Chamuleau R, Legemate D, Mol J, Rothuizen J Metab Brain Dis. 1999; 14(2):103-15.
PMID: 10488912 DOI: 10.1023/a:1020757730386.